Company intelligence / Profile preview
Aluda Pharmaceuticals
Menlo Park, California, United Statesaludapharm.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Aluda’s lead candidate ALD-R491 targets vimentin to modulate immune responses and fibrosis. Preclinical data show significant efficacy in severe models of autoimmune and fibrotic diseases. The company is preparing for Phase I trials in sepsis with plans to expand into Crohn's disease with fibrotic strictures. Animal models demonstrate reversal of fibrosis and restoration of immune balance.[2][3][6][10]
- Therapeutic areas
- ImmunologyGastroenterologyPulmonologyInfectious Diseases
- Modalities
- Small molecules[3][6][7]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Academic collaborations with University of Oxford/Kennedy Institute of Rheumatology [2]Karolinska Institutet [2]
Beyond the preview
Go deeper on Aluda Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aluda Pharmaceuticals.